IDYAIdeaya Biosciences Inc
IDYA
Ideaya Biosciences Inc1,445
Mkt Cap
$2.49BVolume
545,766.0052W High
$39.2852W Low
$16.84PE Ratio
-17.73IDYA Fundamentals
Price
$28.32Prev Close
$28.24Open
$28.2050D MA
$31.78Beta
1.15Avg. Volume
1.71MEPS (Annual)
-$1.28P/B
2.65Rev/Employee
$1.51M$2,447.46
IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) released its earnings results on Tuesday. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.12). The business had revenue of $6.56 million for the quarter, compared to the consensus...
MarketBeat·4d ago
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -3.35% and -35.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update PR Newswire...
PR Newswire·4d ago
IDEAYA Biosciences (IDYA) Projected to Post Earnings on Monday
IDEAYA Biosciences (NASDAQ:IDYA) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at...
MarketBeat·5d ago
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., May 1, 2026 SOUTH SAN FRANCISCO, Calif., May 1, 2026 /PRNewswire/ --IDEAYA Biosciences...
PR Newswire·8d ago
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA lowered its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 28.9% in the fourth quarter, according to its most recent Form 13F filing...
MarketBeat·8d ago
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program IDEAYA...
PR Newswire·9d ago
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.5% - Here's Why
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.5% - Time to Sell...
MarketBeat·18d ago
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma IDEAYA Biosciences Announces Late-Breaking...
PR Newswire·18d ago
IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded IDEAYA Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·21d ago
<
1
2
...
>